MedPage Today reporter Nancy Walsh writes on the current thinking for gout treatment including interleukin (IL)-1β blockade.

"The anti-IL-1 approach to refractory gout remains promising," says Theodore R. Fields, MD, FACP, rheumatologist at HSS.

"It is not surprising that the CANTOS trial showed reduction in gout flares in patients treated with canakinumab. IL-1β has been clearly shown to be a very important mediator of gouty inflammation," Dr. Fields explains.

Read the full article at MedPageToday.com.